News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Kim M. Hirshfield

Articles by Kim M. Hirshfield

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

BySara M. Tolaney, MD, MPH,Paolo D’Amico,Liyi Jia,Kim M. Hirshfield,Fatima Cardoso

April 16th 2025

Latest Updated Articles

Trending on CancerNetwork

Botensilimab/Balstilimab Exhibits Meaningful Activity in Ovarian Cancer

FDA Approves Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma

Novel Agent Shows Early Activity in Phase 2 Recurrent Thymoma Study

Why is Lymphedema Detected So Late in Breast Cancer?

Lu 177 Plus Immunotherapy Displays Responses in Prostate Cancer